Cargando…

Durable Clinical Response of Advanced Lung Adenocarcinoma Harboring EGFR-19del/T790M/BRAF(V600E) Mutations After Treating with Osimertinib and Dabrafenib Plus Trametinib: A Case Report

EGFR-T790M and BRAF(V600E) are the common resistance mechanisms to EGFR-tyrosine kinase inhibitors (TKIs). Standard treatment for the triple mutations of EGFR-19del, T790M, and BRAF(V600E) is still under debate. Herein, we present a case of therapeutic efficacy of osimertinib and dabrafenib plus tra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ding, Honggang, Zhuang, Zhenjie, Xie, Jingyi, Huang, Haifu, Tao, Zhigang, Liu, Zhanhua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7428409/ https://www.ncbi.nlm.nih.gov/pubmed/32848419 http://dx.doi.org/10.2147/OTT.S240775

Ejemplares similares

Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient
por: Ribeiro, Maurício Fernando Silva Almeida, et al.
Publicado: (2021)

A metastatic colon adenocarcinoma harboring BRAF V600E has a durable major response to dabrafenib/trametinib and chemotherapy
por: Williams, Casey B, et al.
Publicado: (2015)

Response to the Combination of Osimertinib, Dabrafenib, and Trametinib in Leptomeningitis From EGFR-Mutant NSCLC With Acquired BRAF V600E Mutation: A Case Report
por: Valet, Orion, et al.
Publicado: (2021)

Combination of Dabrafenib and Trametinib for the Treatment of Relapsed and Refractory Multiple Myeloma Harboring BRAF V600E Mutation
por: Čepulytė, Rūta, et al.
Publicado: (2020)

Response to Dabrafenib and Trametinib of a Patient with Metaplastic Breast Carcinoma Harboring a BRAF V600E Mutation
por: Seo, Takuji, et al.
Publicado: (2020)

Dabrafenib and trametinib therapy in an elderly patient with non‐small cell lung cancer harboring the BRAF V600E mutation
por: Dotsu, Yosuke, et al.
Publicado: (2020)

Rapid and dramatic responses to dabrafenib and trametinib in BRAF V600E‐mutated lung adenocarcinoma
por: Ota, Takayo, et al.
Publicado: (2021)

Dabrafenib, alone or in combination with trametinib, in BRAF V600–mutated pediatric Langerhans cell histiocytosis
por: Whitlock, James A., et al.
Publicado: (2023)

Pretreated EGFR(del19)/BRAF(V600E) Lung Adenocarcinoma With Leptomeningeal Disease Achieving Long-Lasting Disease Control on Osimertinib, Dabrafenib, and Trametinib: A Case Report
por: Orciuolo, Corrado, et al.
Publicado: (2023)

Promising Response to Dabrafenib Plus Trametinib in a Patient with Peritoneal Carcinomatosis from Non Small Lung Cancer Harboring BRAF V600E Mutation
por: Yagami, Yuri, et al.
Publicado: (2022)

FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non‐Small Cell Lung Cancers Harboring BRAF V600E Mutations
por: Odogwu, Lauretta, et al.
Publicado: (2018)

Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation–positive hairy cell leukemia
por: Kreitman, Robert J., et al.
Publicado: (2023)

Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma
por: Rossi, Ernesto, et al.
Publicado: (2019)

Impressive and durable clinical responses obtained with dabrafenib and trametinib in low-grade serous ovarian cancer harbouring a BRAF V600E mutation
por: Lima, Bárbara, et al.
Publicado: (2022)

Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in BRAF(V600E)-Mutated Anaplastic Thyroid Carcinoma
por: Wang, Jennifer R., et al.
Publicado: (2019)

Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600–Mutant Unresectable or Metastatic Melanoma
por: Dummer, Reinhard, et al.
Publicado: (2022)

Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib
por: Noeparast, Amir, et al.
Publicado: (2016)

Granulomatosis with polyangiitis in a patient treated with dabrafenib and trametinib for BRAF V600E positive lung adenocarcinoma
por: Dimou, Anastasios, et al.
Publicado: (2020)

Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in Pediatric BRAF V600–Mutant Low-Grade Glioma
por: Bouffet, Eric, et al.
Publicado: (2023)

An advanced pulmonary sarcomatoid carcinoma patient harboring a BRAF(V600E) mutation responds to dabrafenib and trametinib: a case report and literature review
por: Fang, Ruoxin, et al.
Publicado: (2023)

Dabrafenib-Trametinib and Radiotherapy for Oligoprogressive BRAF Mutant Advanced Melanoma
por: Rossi, Ernesto, et al.
Publicado: (2023)

Dabrafenib Plus Trametinib for BRAF V600E-Mutant Non-small Cell Lung Cancer: A Patient Case Report
por: Pan, Janet
Publicado: (2019)

Partial response to dabrafenib and trametinib in relapsed BRAF V600E-Mutated multiple myeloma and possible mechanisms of resistance
por: Ernst, Tina, et al.
Publicado: (2022)

Population Pharmacokinetics/Pharmacodynamics of Dabrafenib Plus Trametinib in Patients with BRAF-Mutated Metastatic Melanoma
por: Balakirouchenane, David, et al.
Publicado: (2020)

RAS mutation leading to acquired resistance to dabrafenib and trametinib therapy in a multiple myeloma patient harboring BRAF mutation
por: Le Calvez, Baptiste, et al.
Publicado: (2020)

Efficacy of Dabrafenib Plus Trametinib Combination in Patients with BRAF V600E-Mutant NSCLC in Real-World Setting: GFPC 01-2019
por: Auliac, Jean-Bernard, et al.
Publicado: (2020)

Cyclin-dependent kinase 4 upregulation mediates acquired resistance of dabrafenib plus trametinib in BRAF V600E-mutated lung cancer
por: Hirai, Noriko, et al.
Publicado: (2021)

Dramatic Therapeutic Response to Dabrafenib Plus Trametinib in BRAF V600E Mutated Papillary Craniopharyngiomas: A Case Report and Literature Review
por: Fasano, Morena, et al.
Publicado: (2022)

Dabrafenib Plus Trametinib: An Impressive Response in an Adult Patient With BRAF V600E-Mutated and Isocitrate Dehydrogenase (IDH) Wild-Type Glioma
por: Costa, Inês N, et al.
Publicado: (2022)

Dabrafenib and Trametinib prolong coagulation through the inhibition of tissue factor in BRAF(v600e) mutated melanoma cells in vitro
por: Scatena, Cristian, et al.
Publicado: (2019)

Intermittent Dosing of Dabrafenib and Trametinib in Metastatic BRAF(V600E) Mutated Papillary Thyroid Cancer: Two Case Reports
por: White, Paul S., et al.
Publicado: (2017)

Redifferentiation of BRAF V600E-Mutated Radioiodine Refractory Metastatic Papillary Thyroid Cancer After Treatment With Dabrafenib and Trametinib
por: Jafri, Sabih, et al.
Publicado: (2021)

Osimertinib in Combination with Bevacizumab Fails in Advanced Lung Adenocarcinoma Harboring EGFR T790M
por: Zhang, Xiaoying
Publicado: (2021)

Osimertinib for lung cancer cells harboring low-frequency EGFR T790M mutation
por: Joshi, Asim, et al.
Publicado: (2022)

LGG-49. SAFETY AND EFFICACY OF TRAMETINIB (T) MONOTHERAPY AND DABRAFENIB + TRAMETINIB (D+T) COMBINATION THERAPY IN PEDIATRIC PATIENTS WITH BRAF V600-MUTANT LOW-GRADE GLIOMA (LGG)
por: Bouffet, Eric, et al.
Publicado: (2020)

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
por: Long, G. V., et al.
Publicado: (2017)

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
por: Long, G V, et al.
Publicado: (2019)

Retrospective Chart Review of Dabrafenib Plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy)
por: Aglietta, Massimo, et al.
Publicado: (2021)

A Case of Pulmonary Sarcoidosis during First-Line Targeted Therapy with Dabrafenib Plus Trametinib in BRAF V600E-Mutated Metastatic Melanoma
por: Tronconi, Maria Chiara, et al.
Publicado: (2022)

COMBI-r: A Prospective, Non-Interventional Study of Dabrafenib Plus Trametinib in Unselected Patients with Unresectable or Metastatic BRAF V600-Mutant Melanoma
por: Berking, Carola, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7jh0h75e5kdopbkr25gaib3lda